BioCentury
ARTICLE | Finance

March 24 Quick Takes: Apexigen brings series C to $123M; plus Nanjing F&S, FCA and Asieris

March 25, 2020 1:37 AM UTC

Apexigen boosts series C with $65M extension
Apexigen Inc. added $65 million to its 2018 series C, bringing the round to $123 million. The extension was led by Decheng Capital and new investor Oceanpine Capital, with participation from undisclosed new and existing investors. The immuno-oncology company's lead candidate, anti-CD40 mAb APX005M, is in multiple Phase II trials to treat solid tumors.

Yanyuan Capital leads Asieris’ series C
Asieris Pharmaceuticals raised a “multihundred million” renminbi series C round led by Yanyuan Capital Group with participation by Guozhong Venture Capital, Efung Capital, Lapam Capital and Kaitai Capital. The company’s lead candidate APL-1202, a small molecule MetAP2 inhibitor, has completed Phase III testing in China for non-muscle invasive bladder cancer and Phase I testing in the U.S. for the indication. The company plans to complete a series C+ round in the near future...